Ignite Creation Date:
2025-12-24 @ 2:32 PM
Ignite Modification Date:
2026-01-02 @ 11:00 AM
Study NCT ID:
NCT05896059
Status:
RECRUITING
Last Update Posted:
2023-06-09
First Post:
2023-05-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
Sponsor:
Zhejiang Cancer Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-15
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-05-24
First Submit QC Date:
None
Study First Post Date:
2023-06-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-06-06
Last Update Post Date:
2023-06-09
Last Update Post Date Type:
ACTUAL